New safety and behavior findings tied to GLP-1 receptor agonists are raising clinical monitoring questions. Northwestern Medicine research linked GLP-1s to a higher incidence of fainting and dizziness events consistent with hypotensive episodes. A separate ENDO 2026 presentation reported that physical activity declines among adults using GLP-1 medications for weight loss—an unintended effect that could affect downstream cardiometabolic outcomes and adherence strategies. Together, the studies point to off-target or indirect physiologic impacts that clinicians may need to manage beyond weight reduction. For developers and prescribers, these data will likely influence labeling discussions, patient counseling, and risk stratification for patients prone to orthostatic symptoms or reduced activity.